LSPN North America: CRISPR patent pool may emerge, says Regeneron

There has been speculation over whether a patent pool for CRISPR licensing might be created, making it easier for commercial parties to get involved with the technology, according to Larry Coury, senior director of dispute resolution at Regeneron.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

LSPN North America: CRISPR patent pool may emerge, says Regeneron

Editor's picks

Editor's picks

More features